Objectives: To compare the therapeutic effects of gemcitabine (GEM) monotherapy with GEM-cisplatin (DDP) combination chemotherapy in patients with advanced stage pancreatic cancer (APCa) through meta-analysis.
Methods: MEDLINE and EMBASE searches were supplemented by information from trial registers of randomized controlled trials (RCTs) for GEM-DDP combination chemotherapy and GEM alone in APCa. A quantitative meta-analysis using updated information based on inclusion criteria from all available RCTs was carried out by two reviewers. The primary meta-analysis involved the overall survival (OS), objective remission rate (ORR) and toxicity.
Results: The meta-analysis included six RCTs. There was no significant advantage for the GEM-DDP combination group in 6-month survival rate (P = 0.24) or clinical benefit rate (P = 0.58). There was a marginal significant improvement for the GEM-DDP combination group in ORR (RD = 6%, P = 0.05; RD, risk difference = risk in the GEM-DDP combination group - risk in the GEM alone group). Moreover, there was a significant improvement for the combination group in 6-month TTP/TTF (RD = 9%, P = 0.02). WHO grade 3-4 toxicity was higher for the GEM-DDP combination group in terms of neutropenia (RD = 6%, P = 0.08), thrombocytopenia (RD = 8%, P = 0.17) and vomiting/nausea (RD = 11%, P = 0.07); none reached significant difference.
Conclusion: GEM-DDP combination should not be recommended and GEM monotherapy remains the standard treatment for patients with APCa.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1443-9573.2006.00244.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
lncRNA ASBEL and lncRNA Erbb4-IR reduce chemoresistance against gemcitabine and cisplatin in stage IV lung squamous cell carcinoma via the microRNA-21/LZTFL1 axis.
Am J Cancer Res
June 2023
Department of Thoracic Surgery, The Affiliated Hospital of Chengde Medical University Chengde, Hebei, China.
Drug resistance is a major cause of treatment failure and post-treatment disease progression in patients with cancer. This study aimed to investigate the mechanisms of chemoresistance to gemcitabine (GEM) plus cisplatin (cis-diamminedichloroplatinum, DDP) combination therapy in stage IV lung squamous cell carcinoma (LSCC). It also examined the functional role of lncRNA ASBEL and lncRNA Erbb4-IR in the malignant progression of LSCC.
View Article and Find Full Text PDFThe effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transition, invasion and metastasis of pancreatic cancer cells.
Biomed Pharmacother
December 2017
Research Institute of General Surgery, Nanjing School of Clinical Medicine, Southern Medical University (Nanjing General Hospital of Nanjing Military Region), Nanjing, 210002, PR China. Electronic address:
Objective: The study aimed to evaluate the effects involved with the novel chitosan gemcitabine (Gem) nanoparticles mediating cisplatin (DDP) on epithelial mesenchymal transition (EMT), invasion and metastasis of pancreatic cancer (PC) cells.
Methods: A total of 62 healthy purebred BALB/C of specific-pathogen free (SPF) female nude mice were recruited and a SW1990 cell line was subsequently cultured. A heterotopic xenograft tumor model was constructed.
Expression of hENTl and ERCC1 genes in tumor tissues non-small cell lung cancer.
Asian Pac J Trop Med
November 2013
Department of Training, PLA General Hospital, Beijing, China.
Objective: To investigate the expression of hENTl and ERCC1 genes in tumor tissues non-small cell lung cancer (NSCLC).
Methods: Fresh non-small lung cancer specimens were transplanted into nude mice. Twenty mice were randomized into two groups: experimental group receiving gemcitabine plus cisplatin and control group receiving 0.
Meta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine alone.
Chin J Dig Dis
July 2006
Department of Oncology, The Second Affiliated Hospital, Sun Yat-Sen University and Zhongshan People's Hospital, Zhongshan, Guangdong Province, China.
Objectives: To compare the therapeutic effects of gemcitabine (GEM) monotherapy with GEM-cisplatin (DDP) combination chemotherapy in patients with advanced stage pancreatic cancer (APCa) through meta-analysis.
Methods: MEDLINE and EMBASE searches were supplemented by information from trial registers of randomized controlled trials (RCTs) for GEM-DDP combination chemotherapy and GEM alone in APCa. A quantitative meta-analysis using updated information based on inclusion criteria from all available RCTs was carried out by two reviewers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!